Summit Therapeutics (SMMT) Intangibles (2017 - 2022)

Summit Therapeutics (SMMT) has reported Intangibles for 6 consecutive years, with $8.0 million the latest figure, recorded in Q3 2022.

• Quarterly Intangibles fell 25.04% year-over-year to $8.0 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $8.0 million (down 25.04% YoY) and the FY2021 annual result came in at $10.4 million, down 9.69% from the prior year.
• Intangibles slipped to $8.0 million in Q3 2022 per SMMT's latest filing, from $8.9 million in the prior quarter.
• Over the last five years, Intangibles for SMMT reached as high as $20.4 million in Q2 2018 and fell as low as $4.4 million in Q3 2018.
• A 5-year average of $12.0 million and a median of $11.4 million in 2020 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2018 — Intangibles jumped 362.63% — and 2019, when it sank 31.78%.
• Year by year, Intangibles stood at $14.1 million in 2018, then declined by 9.0% to $12.8 million in 2019, then declined by 9.99% to $11.5 million in 2020, then declined by 9.69% to $10.4 million in 2021, then declined by 23.53% to $8.0 million in 2022.
• According to Business Quant data, Intangibles over the past three periods registered $8.0 million, $8.9 million, and $9.9 million for Q3 2022, Q2 2022, and Q1 2022 respectively.